دورية أكاديمية
Cross-protective efficacy and safety of an adenovirus-based universal influenza vaccine expressing nucleoprotein, hemagglutinin, and the ectodomain of matrix protein 2.
| العنوان: | Cross-protective efficacy and safety of an adenovirus-based universal influenza vaccine expressing nucleoprotein, hemagglutinin, and the ectodomain of matrix protein 2. |
|---|---|
| المؤلفون: | Kim J; QuadMedicine Inc., Seongnam, Gyeonggi 13209, Republic of Korea. Electronic address: j.kim@quadmedicine.com., Chang J; Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul 03760, Republic of Korea. Electronic address: tcell@ewha.ac.kr. |
| المصدر: | Vaccine [Vaccine] 2024 May 31; Vol. 42 (15), pp. 3505-3513. Date of Electronic Publication: 2024 May 06. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier Science Country of Publication: Netherlands NLM ID: 8406899 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-2518 (Electronic) Linking ISSN: 0264410X NLM ISO Abbreviation: Vaccine Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Amsterdam, The Netherlands : Elsevier Science Original Publication: [Guildford, Surrey, UK] : Butterworths, [c1983- |
| مواضيع طبية MeSH: | Influenza Vaccines*/immunology , Influenza Vaccines*/administration & dosage , Influenza Vaccines*/genetics , Viral Matrix Proteins*/immunology , Viral Matrix Proteins*/genetics , Adenoviridae*/genetics , Adenoviridae*/immunology , Administration, Intranasal* , Hemagglutinin Glycoproteins, Influenza Virus*/immunology , Hemagglutinin Glycoproteins, Influenza Virus*/genetics , Cross Protection* , Antibodies, Viral*/blood , Antibodies, Viral*/immunology , Orthomyxoviridae Infections*/prevention & control , Orthomyxoviridae Infections*/immunology , Mice, Inbred BALB C*, Animals ; Mice ; Female ; Influenza A Virus, H3N2 Subtype/immunology ; Influenza A Virus, H3N2 Subtype/genetics ; Vaccines, Synthetic/immunology ; Vaccines, Synthetic/administration & dosage ; Vaccines, Synthetic/genetics ; Influenza A Virus, H1N1 Subtype/immunology ; Influenza A Virus, H5N1 Subtype/immunology ; Influenza A Virus, H5N1 Subtype/genetics ; Vaccine Efficacy ; Nucleoproteins/immunology ; Nucleoproteins/genetics ; Viral Core Proteins/immunology ; Viral Core Proteins/genetics ; Injections, Intramuscular ; Viroporin Proteins |
| مستخلص: | It is necessary to develop universal vaccines that act broadly and continuously to combat regular seasonal epidemics of influenza and rare pandemics. The aim of this study was to find the optimal dose regimen for the efficacy and safety of a mixture of previously developed recombinant adenovirus-based vaccines that expressed influenza nucleoprotein, hemagglutinin, and ectodomain of matrix protein 2 (rAd/NP and rAd/HA-M2e). The vaccine efficacy and safety were measured in the immunized mice with the mixture of rAd/NP and rAd/HA-M2e intranasally or intramuscularly. The minimum dose that would be efficacious in a single intranasal administration of the vaccine mixture and cross-protective efficacy against various influenza strains were examined. In addition, the immune responses that may affect the cross-protective efficacy were measured. We found that intranasal administration is an optimal route for 10 7 pfu of vaccine mixture, which is effective against pre-existing immunity against adenovirus. In a study to find the minimum dose with vaccine efficacy, the 10 6 pfu of vaccine mixture showed higher antibody titers to the nucleoprotein than did the same dose of rAd/NP alone in the serum of immunized mice. The 10 6 pfu of vaccine mixture overcame the morbidity and mortality of mice against the lethal dose of pH1N1, H3N2, and H5N1 influenza infections. No noticeable side effects were observed in single and repeated toxicity studies. We found that the mucosal administration of adenovirus-based universal influenza vaccine has both efficacy and safety, and can provide cross-protection against various influenza infections even at doses lower than those previously known to be effective. Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. (Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.) |
| فهرسة مساهمة: | Keywords: Adenovirus vector; Ectodomain of matrix protein 2; Hemagglutinin; Influenza vaccine; Nucleoprotein; Pre-existing immunity |
| المشرفين على المادة: | 0 (M2 protein, Influenza A virus) |
| تواريخ الأحداث: | Date Created: 20240507 Date Completed: 20240519 Latest Revision: 20240528 |
| رمز التحديث: | 20240528 |
| DOI: | 10.1016/j.vaccine.2024.04.054 |
| PMID: | 38714444 |
| قاعدة البيانات: | MEDLINE |
Full Text via ClinicalKey 
Full Text Finder | تدمد: | 1873-2518 |
|---|---|
| DOI: | 10.1016/j.vaccine.2024.04.054 |